2010 GI Intro

Article

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting. See the links below for American Society of Clinical Oncology GI Cancer session cover from GI cancer specialists Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting. See the links below for American Society of Clinical Oncology GI Cancer session cover from GI cancer specialists Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute

Recent Videos
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Related Content
Data from the SEQUOIA trial support the use of zanubrutinib/venetoclax in CLL or SLL regardless of del(17p)/TP53 mutation or IGHV mutational status.

Zanubrutinib Regimen Sustains PFS Benefit Across CLL/SLL Mutation Statuses

Tony Berberabe, MPH
December 9th 2025
Article

Data from the SEQUOIA trial support the use of zanubrutinib/venetoclax in CLL or SLL regardless of del(17p)/TP53 mutation or IGHV mutational status.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Prior bendamustine exposure correlated with worse complete response rates with axi-cel among those with relapsed/refractory follicular lymphoma.

Axi-cel Produces Enduring Real-World Responses in R/R Follicular Lymphoma

Alex Biese
December 9th 2025
Article

Prior bendamustine exposure correlated with worse complete response rates with axi-cel among those with relapsed/refractory follicular lymphoma.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Phase 2 data support further evaluation of frontline BCMA/CD3 bispecific antibody combinations in phase 3 trials.

Teclistamab Combo Elicits Enduring Responses in Transplant-Ineligible NDMM

Courtney Flaherty
December 9th 2025
Article

Phase 2 data support further evaluation of frontline BCMA/CD3 bispecific antibody combinations in phase 3 trials.

After a median follow-up of 3.9 months, AZD0120 elicited an overall response rate of 96% among 23 patients with relapsed/refractory multiple myeloma.

AZD0120 Displays Early Responses/Manageable Safety in R/R Multiple Myeloma

Silas Inman
December 9th 2025
Article

After a median follow-up of 3.9 months, AZD0120 elicited an overall response rate of 96% among 23 patients with relapsed/refractory multiple myeloma.